Gene Editing with CRISPR Training Workshop

Published on :

This remote rigorous three-day program is ideal for basic research and translational biology scientists who are looking for a balanced theoretical vs. laboratory introduction to CRISPR toolkit. Taught by active [….]

Why Philadelphia is Poised to Become a Top Cell and Gene Therapy Cluster

The Discovery Labs King of Prussia PA
Published on :

The Discovery Labs’ 2.4 million square foot site in King of Prussia, PA provides all the necessary ingredients to accelerate speed to market for cell and gene therapy innovators. The Center for Breakthrough Medicines is a cell and gene therapy contract development and manufacturing organization (CDMO) for plasmid DNA, viral vectors, and cellular therapy products and is located on-site.

Rare Disease Challenge, REGENXBIO Tackles Duchenne Muscular Dystrophy

Published on :

Duchenne Muscular Dystrophy is a severe degenerative muscle disease that impacts about one in 5,000 boys per year across the globe. The disease causes a progressive loss of muscle strength attributable to a loss of a protein called dystrophin, which normally protects muscle fibers from breaking down.

5 Questions with Mike O’Mara, VP of Industrial Business Services, Miltenyi Biotec

Published on :

Mike O’Mara has more than 27 years of experience in biopharmaceutical contract manufacturing encompassing microbial, mammalian, and cell/Gene therapy manufacturing processes ranging from Preclinical/Phase I through Commercial.

Why Advanced Biomanufacturing in Maryland is a Thriving Industry

Published on :

Why Advanced Biomanufacturing in Maryland is a Thriving Industry These Four Industry-leading BioManufacturing Companies Represent Thousands of Jobs in Maryland and Are Shaping the Future of Medicine A burgeoning cell [….]

Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability

Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability
Published on :

Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability June 18, 2020 Company acquires property adjacent to its Canton, Massachusetts live viral [….]